Endocrine Abstracts

Background and aims: The most outstanding cardioprotective potential has been demonstrated for GLP-1 receptor agonists (GLP-1RA) and SGLT-2 inhibitors (SGLT-2i). But only long-acting GLP-1RA dulaglutide (DULA) and semaglutide decrease stroke incidence, while data concerning the influence of any drug on stroke severity are lack. At the same time, ischemic stroke remains one of the leading causes of death in type 2 diabetes mellitus (DM2). The aim of our study was to investigate...